The present invention is generally directed to a method for diagnosis, prognosis, or treatment of a cancer, by detecting or upregulating lncRNA, LINC00472. Particularly, LINC00472 is associated with the prognosis of ER-positive breast cancer and is involved in the interplay between ERα and NF-κB.

The invention relates to microbial cells and microbial cells for use as a medicament, the cells expressing a recombinant nucleic acid encoding a eukaryotic tyrosine hydroxylase. The cells produce L-DOPA and dopamine.

The invention relates to microbial cells and microbial cells for use as a medicament, the cells expressing a recombinant nucleic acid encoding a eukaryotic tyrosine hydroxylase. The cells produce L-DOPA and dopamine.

Provided herein are microorganism of a Thraustochytrid and a method for preparing bio-oil using the same, and more particularly, Schizochytrium sp. PB31 (PTA-123692) having bio-oil producibility, and a method of preparing bio-oil, particularly bio-oil having a content of omega-3 and/or 6 long-chain polyunsaturated fatty acids of 30% or more by weight or more based on total fatty acids, characterized by culturing the microorganism.

The present invention relates to novel isolated bacterial strains of the Dolosigranulum pigrum species and variants thereof having at least 99% sequence identity in its 16S rRNA gene to said novel strains. The present invention further relates to the use of these bacterial strains, and compositions comprising said strains for use as a probiotic, such as for improving or restoring the flora/microbiota of the respiratory tract and skin. The present invention further relates to the use of these bacterial strains as an antibacterial agent; for use in human or veterinary medicine; for use in the treatment of human or veterinary diseases; or for use in personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol applications.

The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof. The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.

The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.

The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.

The invention provides compositions and methods for the production of TDP-deoxysugars.